Triple-negative breast cancer (TNBC) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Triple-negative breast cancer (TNBC)

Triple-negative breast cancer (TNBC) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Triple-negative breast cancers (TNBC) are a breast cancer subtype that lacks expression of both estrogen (ER) and progesterone (PR) hormone receptors, as well as human epidermal growth factor receptor 2 (HER2).

Epidemiology-

TNBC comprises 10% of all female breast cancer cases by subtype, which also includes HR+/HER2- disease (68%), HR+/HER2+ disease (10%), HR-/HER2+ disease (4%), and unknown subtype (8%).

As compared to the most common breast cancer subtype HR+/HER2- which is associated with 87 new cases per 100,000 women, the triple-negative subtype accounts for just 13 new cases per 100,000. 5-year relative survival rates can be impacted by subtype and staging.

Despite a total 5-year relative survival rate for all female breast cancers combined of 90%, the relative survival rate for TNBC is the worst at 76.7%.
The stage at diagnosis may be the most powerful factor in determining survival outcome, as shown by relative survival rates for TNBC of 91.2% if the disease is localized, but drops to 11.5% if the disease is distant.

Competitive landscape of Triple-negative breast cancer (TNBC) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Triple-negative breast cancer (TNBC) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Triple-negative breast cancer (TNBC) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Triple-negative breast cancer (TNBC) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 Talimogene Laherparepvec Amgen Phase 1
2 leronlimab CytoDyn, Inc. Phase 2
3 Tumor infiltrating lymphocytes (TIL) LN-145 Iovance Biotherapeutics, Inc. Phase 2
4 LY3023414 and Prexasertib Eli Lilly and Company Phase 2
5 pembrolizumab Merck Sharp & Dohme Corp. Phase 3
6 PMD-026 Phoenix Molecular Designs Phase 1
7 CDX-011 Celldex Therapeutics Phase 2
8 PVX-410 OncoPep, Inc. Phase 2
9 Tak-228 & Tak-117 Takeda Phase 2
10 HX008+Cisplatin+Gemcitabine Taizhou Hanzhong biomedical co. LTD Phase 2
11 AZD2281 AstraZeneca Phase 1
12 Trilaciclib G1 Therapeutics, Inc. Phase 3
13 Magrolimab Gilead Sciences Phase 2
14 Sacituzumab Govitecan Everest Medicines Phase 2
15 TTAC-0001 and pembrolizumab combination PharmAbcine Phase 1
16 Atezolizumab and Nab-Paclitaxel Hoffmann-La Roche Phase 3
17 PQR309 and Eribulin PIQUR Therapeutics AG Phase 2
18 SAR566658 (ACT14884) Sanofi Phase 2
19 NK012 Nippon Kayaku Co., Ltd. Phase 2
20 ENMD-2076 CASI Pharmaceuticals, Inc. Phase 2
21 Apatinib Jiangsu HengRui Medicine Co., Ltd. Phase 2
22 EndoTAG-1 SynCore Biotechnology Co., Ltd. Phase 3
23 KN046 Jiangsu Alphamab Biopharmaceuticals Co., Ltd Phase 2
24 BLEX 404 Oral Liquid BioLite, Inc. Phase 2
25 OTS167PO OncoTherapy Science, Inc. Phase 1
26 Temsirolimus Plus Neratinib Puma Biotechnology, Inc. Phase 2
27 eryaspase ERYtech Pharma Phase 3
28 Niraparib combined with MGD013 Zai Lab (Shanghai) Co., Ltd. Phase 1